18 февраля 2021

We summed up the intermediate results of cooperation with AstraZeneca

256

In June last year, Webiomed, the machine learning-based predictive analytics, and risk management system, won the commercial track of the AstraZeneca Skolkovo StartUpChallenge 2020 acceleration program, which was held by the Skolkovo Foundation and "AstraZeneca".

Because of this victory, we have the opportunity to implement a joint project with the Russian business unit of "AstraZeneca", which actively supports innovative projects and solutions for oncology, cardiovascular diseases, metabolic and renal diseases, respiratory diseases, pathologies of the immune system, gastroenterology as well as digital solutions for the R&D.

The cohort studies of the prevalence, severity, treatment, and outcomes of patients with chronic kidney disease and chronic heart failure were carried out over the course of the joint project. The retrospective analysis of electronic health records with the Webiomed predictive analytics system was performed.

Using machine learning technologies, analysis of anonymized medical data was carried out in order to identify the relationship between individual features. Clinical and demographic characteristics, clinical outcomes, and current treatment regimens for patients with CKD were analyzed using the example of a sample of citizens assigned to three large healthcare facilities in one of the regions of the Russian Federation.

Андрей Саликов“The experience of working with the "AstraZeneca" company has proven that the research development based on the analysis of real clinical data is promising. We would like to thank AstraZeneca for their trust. We are going to continue our active cooperation,” noted Andrey Salikov, Chief Commercial Officer of Webiomed.

Information on companies

AstraZeneca is an international research-oriented biopharmaceutical company dedicated to the research, development, and marketing of prescription drugs primarily in therapeutic areas such as oncology, cardiology, nephrology, and metabolic, respiratory, and autoimmune diseases. AstraZeneca, based in Cambridge, UK, is represented in more than 100 countries around the world, and millions of patients around the world use its innovative products.

Please, rate this article
( 2,94 from 5,
votes: 16)
Yours: Not rate yet

It worth reading

21 Дек 2020

Perinatal risk assessment algorithm has been added to Webiomed

An algorithm that helps doctors determine perinatal risk has been added to the new version of the Webiomed.DHRA clinical decision …

01 Сен 2020

Data for Good - Webiomed project

The Open Systems Publications has launched a special project “DobroData. Data for Good”, dedicated to socially significant data-driven developments. One …

03 Июл 2020

Webiomed is the winner of AstraZeneca Skolkovo StartUp Challenge 2020 in commercial track

The winners of the commercial track of the AstraZeneca Skolkovo StartUp Challenge 2020 acceleration program were determined on July 2. …

Subscribe to our newsletter

Are you interested in digital healthcare and artificial intelligence for medicine? Join our mailing list!

Join us

We are in social networks